{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:05:41Z","timestamp":1790730341390,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008980","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Radiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["European J Hybrid Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The primary aims of this study were to compare in patients with esophageal or esophagogastric junction cancers the potential of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD PET\/CT with that of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT regarding tumoral uptake and distribution, as well as histopathologic examination.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Ten\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD and ten\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT were performed in nine prospectively included participants (1 woman; aged 58\u2009\u00b1\u20098.4 y, range 40\u201369 y). Maximum SUV (SUV\n                      <jats:sub>max<\/jats:sub>\n                      ) and metabolic tumor volumes (MTV) were calculated. The Mann\u2013Whitney U test and Spearman correlation analysis (\n                      <jats:italic>\u03c1<\/jats:italic>\n                      ) were used.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD PET\/CT detected positive uptake in 10 primary sites (8 for primary tumors and 2 for local relapse suspicion), 6 lymph nodes and 3 skeletal sites.\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT detected positive uptake in the same sites but also in 16 additional lymph nodes and 1 adrenal gland. On a lesion-based analysis, SUV\n                      <jats:sub>max<\/jats:sub>\n                      of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG was significantly higher than those of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD (4.9 [3.7\u201311.3] vs. 3.2 [2.6\u20134.2] g\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014). Only one participant showed a higher SUV\n                      <jats:sub>max<\/jats:sub>\n                      in an osseous metastasis with\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD as compared to\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG (6.6 vs. 3.9\u00a0g\/mL). Correlation analysis showed positive correlation between\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD PET parameters (\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u2009=\u20090.56,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012 for SUV\n                      <jats:sub>max<\/jats:sub>\n                      ,\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u2009=\u20090.78,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 for lesion-to-background ratios and\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u2009=\u20090.58,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.024 for MTV). We observed that\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG uptake was homogenous inside all the confirmed primary sites (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099). In contrast,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD PET showed more heterogenous uptake in 6 out of the 9 confirmed primary sites (67%), seen mostly in the periphery of the tumor in 5 out of the 9 confirmed primary sites (56%), and showed slight extensions into perilesional structures in 5 out of the 9 confirmed primary sites (56%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In conclusion,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-NODAGA-RGD has lower potential in the detection of esophageal or esophagogastric junction malignancies compared to\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG. However, the results suggest that PET imaging of integrin\n                      <jats:italic>\u03b1<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>v<\/jats:italic>\n                      <\/jats:sub>\n                      <jats:italic>\u03b2<\/jats:italic>\n                      <jats:sub>3<\/jats:sub>\n                      expression may provide complementary information and could aid in tumor diversity and delineation.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration:<\/jats:italic>\n                      Trial registration: NCT02666547. Registered January 28, 2016\u2014Retrospectively registered,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02666547\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02666547<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41824-023-00162-9","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T19:09:01Z","timestamp":1675192141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of integrin \u03b1v\u03b23 expression with 68Ga-NODAGA-RGD PET\/CT and glucose metabolism with 18F-FDG PET\/CT in esophageal or gastroesophageal junction cancers"],"prefix":"10.1186","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02666547","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Matthieu","family":"Dietz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Dunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Mantziari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Pomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Dias Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Testart Dardel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Boughdad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Nicod Lalonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-7696","authenticated-orcid":false,"given":"Niklaus","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Prior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"162_CR1","doi-asserted-by":"publisher","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","volume":"17","author":"JA Ajani","year":"2019","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Corvera C, Das P et al (2019) Esophageal and esophagogastric junction cancers, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 17:855\u2013883. https:\/\/doi.org\/10.6004\/jnccn.2019.0033","journal-title":"J Natl Compr Canc Netw"},{"key":"162_CR2","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","volume":"69","author":"M Arnold","year":"2020","unstructured":"Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I (2020) Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut 69:1564\u20131571. https:\/\/doi.org\/10.1136\/gutjnl-2020-321600","journal-title":"Gut"},{"key":"162_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2967\/jnumed.107.045864","volume":"49","author":"AJ Beer","year":"2008","unstructured":"Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ et al (2008) Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 49:22\u201329. https:\/\/doi.org\/10.2967\/jnumed.107.045864","journal-title":"J Nucl Med"},{"key":"162_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s00259-014-2891-7","volume":"42","author":"A Bozon-Petitprin","year":"2015","unstructured":"Bozon-Petitprin A, Bacot S, Gauchez AS, Ahmadi M, Bourre JC, Marti-Batlle D et al (2015) Targeted radionuclide therapy with RAFT-RGD radiolabelled with 90Y or 177Lu in a mouse model of \u03b1v\u03b23-expressing tumours. Eur J Nucl Med Mol Imaging 42:252\u2013263. https:\/\/doi.org\/10.1007\/s00259-014-2891-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"162_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"162_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3413\/Nukmed-0416-11-06","volume":"50","author":"F Buchegger","year":"2011","unstructured":"Buchegger F, Viertl D, Baechler S, Dunet V, Kosinski M, Poitry-Yamate C et al (2011) 68Ga-NODAGA-RGDyK for \u03b1v\u03b23 integrin PET imaging. Preclinical investigation and dosimetry. Nuklearmedizin 50:225\u2013233. https:\/\/doi.org\/10.3413\/Nukmed-0416-11-06","journal-title":"Nuklearmedizin"},{"key":"162_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7150\/thno.13242","volume":"6","author":"H Chen","year":"2016","unstructured":"Chen H, Niu G, Wu H, Chen X (2016) Clinical application of radiolabeled RGD peptides for PET imaging of integrin \u03b1v\u03b23. Theranostics 6:78\u201392. https:\/\/doi.org\/10.7150\/thno.13242","journal-title":"Theranostics"},{"key":"162_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13550-021-00815-5","volume":"11","author":"M Dietz","year":"2021","unstructured":"Dietz M, Kamani CH, Deshayes E, Dunet V, Mitsakis P, Coukos G et al (2021) Imaging angiogenesis in atherosclerosis in large arteries with 68Ga-NODAGA-RGD PET\/CT: relationship with clinical atherosclerotic cardiovascular disease. EJNMMI Res 11:71. https:\/\/doi.org\/10.1186\/s13550-021-00815-5","journal-title":"EJNMMI Res"},{"key":"162_CR9","doi-asserted-by":"publisher","first-page":"887508","DOI":"10.3389\/fmed.2022.887508","volume":"9","author":"M Dietz","year":"2022","unstructured":"Dietz M, Kamani CH, Dunet V, Fournier S, Rubimbura V, Testart Dardel N et al (2022) Overview of the RGD-Based PET agents use in patients with cardiovascular diseases: a systematic review. Front Med Lausanne 9:887508. https:\/\/doi.org\/10.3389\/fmed.2022.887508","journal-title":"Front Med Lausanne"},{"key":"162_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13550-020-00638-w","volume":"10","author":"S Durante","year":"2020","unstructured":"Durante S, Dunet V, Gorostidi F, Mitsakis P, Schaefer N, Delage J et al (2020) Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET\/CT: a pilot study. EJNMMI Res 10:47. https:\/\/doi.org\/10.1186\/s13550-020-00638-w","journal-title":"EJNMMI Res"},{"key":"162_CR11","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s00259-020-04975-9","volume":"48","author":"T Ebenhan","year":"2021","unstructured":"Ebenhan T, Kleynhans J, Zeevaart JR, Jeong JM, Sathekge M (2021) Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents. Eur J Nucl Med Mol Imaging 48:1414\u20131433. https:\/\/doi.org\/10.1007\/s00259-020-04975-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"285","key":"162_CR12","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"18","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 18(285):1182\u20131186. https:\/\/doi.org\/10.1056\/NEJM197111182852108","journal-title":"N Engl J Med"},{"key":"162_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","volume":"20","author":"CS Fuchs","year":"2019","unstructured":"Fuchs CS, Shitara K, Bartolomeo MD, Lonardi S, Al-Batran SE, Cutsem EV et al (2019) Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 20:420\u2013435. https:\/\/doi.org\/10.1016\/S1470-2045(18)30791-5","journal-title":"Lancet Oncol"},{"issue":"383","key":"162_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"2014","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Trial Investigators REGARD et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014(383):31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(13)61719-5","journal-title":"Lancet"},{"key":"162_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13550-017-0288-x","volume":"7","author":"S Gnesin","year":"2017","unstructured":"Gnesin S, Mitsakis P, Cicone F, Deshayes E, Dunet V, Gallino AF et al (2017) First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK. EJNMMI Res 7:43. https:\/\/doi.org\/10.1186\/s13550-017-0288-x","journal-title":"EJNMMI Res"},{"key":"162_CR16","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00259-016-3396-3","volume":"43","author":"R Haubner","year":"2016","unstructured":"Haubner R, Finkenstedt A, Stegmayr A, Rangger C, Decristoforo C, Zoller H et al (2016) [68Ga]NODAGA-RGD \u2013 Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. Eur J Nucl Med Mol Imaging 43:2005\u20132013. https:\/\/doi.org\/10.1007\/s00259-016-3396-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"162_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrc727","volume":"2","author":"JD Hood","year":"2002","unstructured":"Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91\u2013100. https:\/\/doi.org\/10.1038\/nrc727","journal-title":"Nat Rev Cancer"},{"key":"162_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1148\/radiol.14140028","volume":"273","author":"A Iagaru","year":"2014","unstructured":"Iagaru A, Mosci C, Shen B, Chin FT, Mittra E, Telli ML et al (2014) 18F-FPPRGD2 PET\/CT: pilot phase evaluation of breast cancer patients. Radiology 273:549\u2013559. https:\/\/doi.org\/10.1148\/radiol.14140028","journal-title":"Radiology"},{"key":"162_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.2967\/jnumed.107.047423","volume":"49","author":"JM Jeong","year":"2008","unstructured":"Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon GJ et al (2008) Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 49:830\u2013836. https:\/\/doi.org\/10.2967\/jnumed.107.047423","journal-title":"J Nucl Med"},{"key":"162_CR20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s42003-021-02003-6","volume":"4","author":"Y Kariya","year":"2021","unstructured":"Kariya Y, Oyama M, Suzuki T, Kariya Y (2021) \u03b1v\u03b23 Integrin induces partial EMT independent of TGF-\u03b2 signaling. Commun Biol 4:490. https:\/\/doi.org\/10.1038\/s42003-021-02003-6","journal-title":"Commun Biol"},{"key":"162_CR21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00259-011-1778-0","volume":"38","author":"PA Knetsch","year":"2011","unstructured":"Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C et al (2011) [68Ga]NODAGA-RGD for imaging \u03b1v\u03b23 integrin expression. Eur J Nucl Med Mol Imaging 38:1303\u20131312. https:\/\/doi.org\/10.1007\/s00259-011-1778-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"162_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ddr.20265","volume":"69","author":"Z Liu","year":"2008","unstructured":"Liu Z, Wang F, Chen X (2008) Integrin alpha(v)beta(3)-targeted cancer therapy. Drug Dev Res 69:329\u2013339. https:\/\/doi.org\/10.1002\/ddr.20265","journal-title":"Drug Dev Res"},{"key":"162_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-017-0742-4","volume":"16","author":"Q Liu","year":"2017","unstructured":"Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D (2017) Factors involved in cancer metastasis: a better understanding to \u201cseed and soil\u201d hypothesis. Mol Cancer 16:176. https:\/\/doi.org\/10.1186\/s12943-017-0742-4","journal-title":"Mol Cancer"},{"key":"162_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/SLA.0b013e3181c97fcf","volume":"251","author":"G Lurje","year":"2010","unstructured":"Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Ayazi S et al (2010) Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg 251:857\u2013864. https:\/\/doi.org\/10.1097\/SLA.0b013e3181c97fcf","journal-title":"Ann Surg"},{"key":"162_CR25","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.7150\/thno.12938","volume":"5","author":"B Mi","year":"2015","unstructured":"Mi B, Yu C, Pan D, Yang M, Wan W, Niu G et al (2015) Pilot Prospective evaluation of 18F-alfatide II for detection of skeletal metastases. Theranostics 5:1115\u20131121. https:\/\/doi.org\/10.7150\/thno.12938","journal-title":"Theranostics"},{"key":"162_CR26","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1007\/s00259-015-3096-4","volume":"42","author":"R Minamimoto","year":"2015","unstructured":"Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mittra E, Shen B et al (2015) Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. Eur J Nucl Med Mol Imaging 42:1850\u20131858. https:\/\/doi.org\/10.1007\/s00259-015-3096-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"162_CR27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fcell.2020.00584","volume":"7","author":"C Montemagno","year":"2020","unstructured":"Montemagno C, Pag\u00e8s G (2020) Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs. Front Cell Dev Biol 7(8):584. https:\/\/doi.org\/10.3389\/fcell.2020.00584","journal-title":"Front Cell Dev Biol"},{"key":"162_CR28","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/neuonc\/nou356","volume":"17","author":"LB Nabors","year":"2015","unstructured":"Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH et al (2015) Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol 17:708\u2013717. https:\/\/doi.org\/10.1093\/neuonc\/nou356","journal-title":"Neuro Oncol"},{"key":"162_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.nucmedbio.2012.02.006","volume":"39","author":"K Pohle","year":"2012","unstructured":"Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ (2012) 68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP\/GRP compliant automated process. Nucl Med Biol 39:777\u2013784. https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.02.006","journal-title":"Nucl Med Biol"},{"key":"162_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.tranon.2019.04.022","volume":"12","author":"D Ribatti","year":"2019","unstructured":"Ribatti D, Annese T, Ruggieri S, Tamma R, Crivellato E (2019) Limitations of anti-angiogenic treatment of tumors. Transl Oncol 12:981\u2013986. https:\/\/doi.org\/10.1016\/j.tranon.2019.04.022","journal-title":"Transl Oncol"},{"key":"162_CR31","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071\u201322072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1100\u20131108. https:\/\/doi.org\/10.1016\/S1470-2045(14)70379-1","journal-title":"Lancet Oncol"},{"key":"162_CR32","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2967\/jnumed.109.067140","volume":"50","author":"TJ Wadas","year":"2009","unstructured":"Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ (2009) Targeting the \u03b1v\u03b23 integrin for small-animal PET\/CT of osteolytic bone metastases. J Nucl Med 50:1873\u20131880. https:\/\/doi.org\/10.2967\/jnumed.109.067140","journal-title":"J Nucl Med"},{"key":"162_CR33","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, RAINBOW Study Group et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6","journal-title":"Lancet Oncol"},{"key":"162_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12149-018-1315-3","volume":"33","author":"S Zheng","year":"2019","unstructured":"Zheng S, Chen Z, Huang C, Chen Y, Miao W (2019) [99mTc]3PRGD2 for integrin receptor imaging of esophageal cancer: a comparative study with [18F]FDG PET\/CT. Ann Nucl Med 33:135\u2013143. https:\/\/doi.org\/10.1007\/s12149-018-1315-3","journal-title":"Ann Nucl Med"},{"key":"162_CR35","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/annrheumdis-2013-204820","volume":"73","author":"Z Zhu","year":"2014","unstructured":"Zhu Z, Yin Y, Zheng K, Li F, Chen X, Zhang F et al (2014) Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET\/CT: a prospective proof-of-concept cohort study. Ann Rheum Dis 73:1269\u20131272. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204820","journal-title":"Ann Rheum Dis"}],"container-title":["European Journal of Hybrid Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-023-00162-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-023-00162-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-023-00162-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T19:15:01Z","timestamp":1675192501000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-023-00162-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1186\/s41824-023-00162-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2272316\/v1","asserted-by":"object"}]},"ISSN":["2510-3636"],"issn-type":[{"value":"2510-3636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its last amendments or comparable ethical standards. This study was approved by the ethics commission Vaud (protocol CER-VD #120\/12). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participants signed informed consent regarding publishing their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}